Company IRLAB Therapeutics AB

IRLAB A

SE0012675361

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 12/06/2026 BST			5-day change	1st Jan Change
1.242 ^SEK	-2.05%		-2.05%	-36.95%

06-08	Irlab shares trade ex-rights on Nasdaq Stockholm following rights issue	FW
06-05	IRLAB Therapeutics AB Announces Board Elections, Effective June 5, 2026	CI

Business description: IRLAB Therapeutics AB

IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinsonâ€™s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinsonâ€™s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

Number of employees: 31

Sales by Activity: IRLAB Therapeutics AB

Fiscal Period: December	2020 (SEK)	2021 (SEK)	2022 (SEK)	2023 (SEK)	2024 (SEK)
Pharmaceuticals	300K	208M	61.14M	5.68M	94.63M

See all business segments

Geographical breakdown of sales: IRLAB Therapeutics AB

Fiscal Period: December	2020 (SEK)	2021 (SEK)	2022 (SEK)	2023 (SEK)	2024 (SEK)
United States	-	-	-	4.22M	94.63M
United Kingdom	-	208M	61.14M	1.46M	-
Sweden	300K	-	-	-	-

See all geographic segments

Executive Committee: IRLAB Therapeutics AB

Manager	Title	Age	Since
Kristina Torfgård CEO	Chief Executive Officer	63	31/07/2024
Susanna Waters PRN	Corporate Officer/Principal	60	31/12/2012
Clas Sonesson CTO	Chief Tech/Sci/R&D Officer	65	31/12/2015
Nicholas Waters CEO	Chief Executive Officer	64	31/12/2012
Gustaf Albért DFI	Director of Finance/CFO	58	16/11/2025

See IRLAB THERAPEUTICS AB governance

Composition of the Board of Directors: IRLAB Therapeutics AB

Director	Title	Age	Since
Rein Piir BRD	Director/Board Member	68	31/12/2015
Gunnar Olof Olsson CHM	Chairman	73	06/05/2020
Carola Elisabet Lemne CHM	Chairman	68	19/02/2023
Christer Nordstedt BRD	Director/Board Member	64	31/12/2022
Veronica Wallin BRD	Director/Board Member	40	31/12/2022

Composition of the Board of Directors

Shareholders: IRLAB Therapeutics AB

Name	Stocks	%	Valuation
ISEC Services AB 0.1902 %	161,423	0.1902 %	21 364 kr
FCG Fonder AB 0.0115 %	9,718	0.0115 %	1 286 kr

List of IRLAB THERAPEUTICS AB shareholders

Company details: IRLAB Therapeutics AB

IRLAB Therapeutics AB

Arvid Wallgrens Backe 20

413 46, Gothenburg

+46 3 17 57 38 00

http://www.irlab.se

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRLAB THERAPEUTICS AB	-2.05%	-2.05%	-82.18%	-83.91%	11.23M
ELI LILLY AND COMPANY	-2.41%	+0.14%	+38.28%	+154.20%	1,010B
JOHNSON & JOHNSON	+1.07%	+3.48%	+53.32%	+49.85%	580B
ABBVIE INC.	+1.32%	+0.22%	+19.18%	+64.65%	402B
ROCHE HOLDING AG	+0.77%	0.00%	+21.28%	+16.70%	330B
NOVARTIS AG	+0.44%	+3.48%	+25.65%	+35.66%	281B
ASTRAZENECA PLC	-0.85%	-2.86%	+22.54%	+14.67%	280B
NOVO NORDISK A/S	+1.66%	+1.20%	-44.35%	-47.35%	197B
AMGEN INC.	+0.32%	+1.61%	+20.32%	+60.01%	192B
GILEAD SCIENCES, INC.	-0.22%	-2.76%	+14.19%	+60.09%	156B
Average	+0.01%	+0.77%	+8.82%	+32.46%	342.89B
Weighted average by Cap.	-0.23%	+1.04%	+27.77%	+70.54%